# Qwen 3.8 27B — deep_reasoning/ethical_dilemma_structured

- model_id: `qwen/qwen3.8-27b`
- success: True  | final: 6.71 | quality: 7.5
- latency_total: 32.578s | tokens_per_second: 77.4
- input_tokens: 234 | output_tokens: 2522

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa

We need answer in Spanish. User asks: startup AI cancer detection 95% precision. Issues: 5% false positives cause anxiety and unnecessary procedures; model worse in darker skin 90% vs 97% light skin; launch now saves lives but known bias; wait 6 months means people die. Board asks recommendation. Structure: 1 stakeholders, 2 quantitative trade-offs, 3 options pros/cons, 3? actually 4 final recommendation justified. "No busques la respuesta 'correcta' - busca la mejor argumentada." Need provide well-argued. Need think carefully. We need maybe discuss precision vs sensitivity? They only give precision. Need be careful: cancer detection model precision 95% means PPV? If 95% precision, 5% false positives among positive calls. But also need false negatives? Not given. We can state assumptions. Need quantitative trade-offs maybe use hypothetical population, base rates. We can create scenario: 100,000 screened, prevalence 1%? If precision 95%, positive predictive value. Need false positives cause harm. Bias: 90% precision in dark skin vs 97% light. If equal prevalence and equal positive rate? Need quantify. Could choose illustrative numbers: 100k people, 1% cancer prevalence = 1000 cancers. If model detects with sensitivity? Precision alone insufficient. We can assume sensitivity 95%? Or use precision to estimate positives. Maybe better to define metrics: precision = TP/(TP+FP). If 95% precision, for every 100 positive results, 95 true cancers, 5 false positives. But absolute false positives depends on number of positives and prevalence. Need trade-off: false positives vs missed cancers. Bias: dark skin 90% precision means for 100 positive results, 10 false positives vs 3 for light. If dark population screened, more false positives. Also if worse performance could mean lower sensitivity too? They only say precision. We can mention precision bias may be due to lower sensitivity or higher false positives; need measure both. But for board, use available numbers. Need maybe propose staged launch with risk-based use, consent, monitoring, not blanket launch or wait. Option 1: launch now for all with clear warnings and mitigation. Option 2: wait 6 months. Option 3: targeted/conditional launch: launch in high-risk groups/clinical settings with confirmatory testing, prioritize dark skin, audit, maybe use as triage not diagnosis. Or option 3: launch with equity constraint and rapid remediation, maybe only where false positive follow-up safe. Need 3 options. Recommendation likely conditional launch with safeguards, not wait, not unmitigated. Need justify with ethics: utilitarian, justice, nonmaleficence, autonomy, accountability. Need quantify: lives saved vs deaths from waiting. Need maybe use QALY/harm weights. Could define:
- Assume screening 100,000 over 6 months, prevalence 1%, sensitivity 95%, specificity 90? Need align precision. Let's construct coherent numbers.
Given precision 95% overall. Suppose sensitivity 95%, specificity 95? Let's compute PPV. Prevalence 1%, sensitivity 95%, specificity 95%: TP=950, FN=50, FP=950, TN=98550. Precision=950/(950+950)=50%, not 95. To have precision 95% with prevalence 1%, need very high specificity or only screen high-risk. If high-risk prevalence 20%, sensitivity 95, specificity 95: TP=3800, FP=400, precision=90.4. To get 95 precision at prevalence 20%, specificity 98: TP=3800, FP=152, precision=96.2. Maybe not need exact.
Alternative: Use positive calls: If 10,000 positive calls, 950 true, 500 false. If 1,000 true cancers detected, 50 false positives. But need false negatives. Could say model's precision 95% means among positive alerts, 5% are false; if it alerts 10,000, 500 unnecessary procedures. But cancer detection also false negatives. Need mention precision alone doesn't capture missed cancers; board needs sensitivity/NPV. But can still quantify false positives.
Maybe create a table: For 10,000 positive alerts:
- Overall: 9,500 true, 500 false positives.
- If 10% of users are dark skin? Actually precision 90 vs 97. If equal number positive alerts in groups: 1,000 positive alerts dark -> 90 true, 10 false; 9,000 light -> 873 true, 27 false; total 963 true, 37 false (overall 96.3 precision). Not 95. Need adjust. We can just illustrate bias increment: for every 100 positive alerts to dark-skin patients, 10 false positives vs 3 for light. If dark-skin patients receive 20% of alerts, excess false positives = (0.10-0.03)*2000? Let's do: 10,000 alerts, 20% dark=2,000. False positives dark=200; if light precision 97 would be 60; excess 140. So bias causes ~140 extra false positives per 10k alerts if 20% dark. If dark 50%, excess = (10%-3%)*5,000=350. But also if precision lower due to missed cancers? Need be clear.
Need maybe quantify lives saved vs deaths waiting. We can use assumptions: model detects X additional cancers earlier. Suppose in 6 months, 100,000 screened, 1,000 cancers, model sensitivity 95% vs current 80%? It detects 150 more early, 5-year survival 80% vs 20%? Lives saved = 150*0.6=90. If wait 6 months, those 90 die. False positives: 500 per 100k? Harm: anxiety, procedures. Weight false positive harm as e.g. 0.05 QALY loss vs death 1 QALY? Then 500*0.05=25 QALY harm vs 90 QALY benefit. But need not overdo? User asks analyze quantitatively. We can provide a transparent model with assumptions, sensitivity analysis.
Need maybe include base rate and risk stratification. Since precision 95% likely in high-risk or positive alerts. We can define "positive alert" not all screened. Quantify per 10,000 positive alerts:
- Overall: 500 false positives.
- Bias: if 20% dark, 200 FP; if all had 97% precision, 60; excess 140. If 50% dark, excess 350.
- False positives cause: biopsy complications, anxiety. Assign weight: severe anxiety + unnecessary procedure = 0.02-0.1 QALY? Death = 1 QALY (or 10 years). Need compare.
But also false negatives: if dark skin 90% precision vs 97 light, if same sensitivity? Precision lower could mean more false positives or fewer true positives. If due to lower sensitivity, missed cancers in dark skin: For every 100 cancers in dark group, maybe? Need not know. We can say need measure sensitivity. But can illustrate: If 1,000 cancers in dark group and sensitivity 90% vs 97%, 70 missed vs 30 missed; excess 40 missed cancers. If survival benefit 50%, 20 excess deaths. This is important: bias may cause deaths in dark skin. Need include.
Maybe create a decision matrix with options:
A) Launch now unrestricted. Pros: saves lives immediately; revenue; learning. Cons: 5% FP, bias harms, liability, erosion trust, regulatory.
B) Wait 6 months. Pros: fix bias, fewer FP, stronger trust. Cons: preventable deaths, competitor, model staleness, ethical cost.
C) Conditional launch with equity safeguards: use as assistive/triage, confirmatory test, higher threshold for dark skin? But careful: adjusting thresholds can trade off sensitivity/specificity; must not reduce detection for dark skin. Instead calibrate, collect data, audit, limit initial population to settings where follow-up is safe, require clinician oversight, prioritize high-risk, transparent consent, stop rules. Pros: saves lives, reduces harm, builds data, equity. Cons: complexity, cost, still some harm, may delay some.
Maybe option D? Need 3 options. Could include "launch only for light-skin?" That's unjust. Better not. But maybe options: 1 launch now all; 2 wait; 3 phased/conditional. Recommendation 3.
Need structure exactly: 1 stakeholders, 2 quantitative trade-offs, 3 options pros/cons, 4 recommendation. Could add "supuestos" before quantitative. Need be rigorous: precision vs sensitivity, base rate. Use per 10,000 positive alerts and per 100,000 screened? Let's design a coherent quantitative example.
Let's choose a screening population: 100,000 high-risk individuals over 6 months, prevalence 20%? That yields enough positives. But cancer detection maybe not all high-risk. Let's define:
- 100,000 screenings in 6 months.
- True cancer prevalence: 2% = 2,000 cancers.
- Model sensitivity: 95% (assumed) -> detects 1,900, misses 100.
- To achieve 95% precision, false positives must be: TP/(TP+FP)=0.95 => FP = TP*(0.05/0.95)=1,900*0.05263=100. So specificity = (100,000-2,000-100)/(98,000)=97,900/98,000=99.898%. That's high but possible in high-risk. Then positive alerts = 2,000 (1,900 TP + 100 FP). Precision 95%. False positives = 100. This is small. But user says 5% false positives cause severe anxiety. If 100 per 100k, maybe not huge. But if positive alerts 10,000, FP 500. Could use positive alerts as unit simpler.
But if bias: dark skin precision 90, light 97. Suppose overall 95. Need mixture. Let fraction dark positive alerts p. Overall precision = p*0.90 + (1-p)*0.97 = 0.95 => 0.97 -0.07p=0.95 => p=0.0286. That implies only 2.86% of